Abstract: A tire inspection system includes a data acquisition unit, a groove depth determination unit, and an alert processing unit. The data acquisition unit acquires data for groove depth derived from measuring a groove depth of a tire mounted on a vehicle a plurality of times per groove by using the measurement instrument. The groove depth determination unit determines whether a per-groove difference in groove depth acquired by the data acquisition unit is equal to or larger than a predetermined value. When the groove depth determination unit determines that the difference is equal to or larger than the predetermined value, the alert processing unit outputs an alert to indicate that the groove depth should be measured again.

Abstract: A tire inspection system includes a data acquisition unit, a user operation acknowledgment unit, and a display processing unit. The data acquisition unit acquires data for groove depth measured by a groove depth measurement instrument for measuring a groove depth of a tire. The user operation acknowledgment unit acknowledges a user operation input provided by a worker to indicate whether an uneven wear is identified in the tire for which the data for groove depth is acquired by the data acquisition unit. The display processing unit displays, when a user operation input acknowledged by the user operation acknowledgment unit indicates that an uneven wear is identified, a schematic diagram corresponding to a plurality of types of uneven wear. The user operation acknowledgment unit acknowledges a user operation input for the worker's selection of a type of uneven wear from the schematic diagram.

Abstract: A friction material includes a fiber base material, a friction modifier and a binder. The friction modifier includes two or more kinds of titanate compounds. The two or more kinds of titanate compounds have a median diameter (D50) of 20 ?m or more. At least one of the two or more kinds of titanate compounds is a porous titanate compounds. The friction material includes no copper component.

Abstract: A friction material includes a fiber base material, a friction modifier and a binder. The friction modifier includes two or more kinds of titanate compounds. The two or more kinds of titanate compounds have a median diameter (D50) of 20 ?m or more. At least one of the two or more kinds of titanate compounds is a porous titanate compounds. The friction material includes no copper component.

Abstract: A bottomed conical hollow 6b is formed in a tip end of the container body A formed of a thermoplastic material with a liquid filled and sealed therein simultaneously during the molding process, the hollow having an inside diameter enlarging toward the tip end, and a small-diameter instilling hole 6c is penetrated through the bottom of the hollow 6b for controlling, at a set quantity, the liquid pushed out of the container body A.

Abstract: In an eye drops container, a barrel portion 2 in the form of a flexible hollow cylinder defines a dent portion 7 which can be gripped with two fingers.

Abstract: For sealing a container (2) consisting of a barrel portion (3) and a cap portion (4) threaded and tightened on the barrel portion, the sealing label (1) includes a lower portion (1A) for substantially wrapping the barrel portion and an upper portion (1B) for substantially wrapping the cap portion. The sealing label includes horizontal perforations (10) consisting of cut segments (11) and uncut segments (12; 13) extending along a border between the upper portion and the lower portion; a knob portion (1a) disposed at an edge of the upper portion; and inclined perforations (20) consisting of cut segments (21) and uncut segments (22) extending obliquely in the upper portion from the knob portion to the horizontal perforations.

Abstract: An ophthalmic composition particularly in the form of eye-drops suitable for the treatment of diseases of the eye and surrounding areas. The composition contains a cyclosporin and a surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenyl ethers and polyoxyethylene alkyl ethers, or mixtures thereof.

Abstract: A shock absorber comprising a honeycomb block with a plurality of cylindrical cell arranged in parallel, wherein the strength of said honeycomb block to withstand the load in the cell axial direction is adjusted by a processed configuration of said cells.

Abstract: An ophthalmic composition particularly in the form of eye-drops suitable for the treatment of diseases of the eye and surrounding areas. The composition contains a cyclosporin and a surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenyl ethers and polyoxyethylene alkyl ethers, or mixtures thereof.

Abstract: The present invention relates to compounds represented by the formula [I] and salts thereof, wherein R.sup.1 and R.sup.5 each represents carboxyl, phosphonic or a derivative thereof; R.sup.2 represents hydrogen, lower alkyl, (substituted) phenyl lower alkyl, lower alkoxy or (substituted) phenyl lower alkoxy; R.sup.3 represents lower alkyl or (substituted) phenyl lower alkyl; and R.sup.4 represents a group represented by the formula [XI], [XII] or [XIII]. The compounds of the present invention have endopeptidase 24.11 inhibitory activity and are useful for treating cardiovascular diseases such as heart failure and hypertension, renal diseases such as renal failure, gastroenteric disorders such as diarrhea and hyperchlorhydria, endocrine and metabolic diseases such as obesity, and autoimmune diseases such as rheumatic disease, and for mitigating myosalgia, migraine, etc.

Abstract: A sealed container stores therein liquid such as eye drops in a sealed state. For dispensing the liquid first time, the factory-sealed outlet of the liquid is to be unsealed with a needled of a liquid discharge plug fitted within a cap in association with a user's operation of the cap in a loosening or tightening direction when the liquid is first dispensed therefrom. The container includes a one-way rotation preventing mechanism provided respectively at mutually opposing portions of a liquid discharge plug prefitted with the cap and the container. This mechanism prevents rotation of the liquid discharge plug in the loosening direction of the cap while allowing rotation thereof in the screwing direction of the cap when the cap has been tightened to a predetermined screwing position immediately before the needle initiates it penetrating action into the sealed liquid outlet.

Abstract: An ophthalmic composition particularly in the form of eye-drops suitable for the treatment of diseases of the eye and surrounding areas. The composition contains a cyclosporin and a surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenyl ethers and polyoxyethylene alkyl ethers, or mixtures thereof.

Abstract: The present invention related to compounds represented by the following formula (I) and salts thereof, ##STR1## wherein R.sup.1 and R.sup.4 each represents a carboxyl or a carboxyl which is converted into an ester, an amide or hydroxamic acid; R.sup.2 represents a lower alkyl or a phenyl-lower alkyl; R.sup.3 represents a hydrogen atom, a lower alkyl, an amino-lower alkyl, a lower alkylamino-lower alkyl, a hydroxy-lower alkyl, a mercapto-lower alkyl, a carboxy-lower alkyl, a lower alkoxycarbonyl-lower alkyl, an imidazolyl-lower alkyl, an indolyl-lower alkyl, a (substituted) phenyl group, a (substituted) phenyl-lower alkyl group, a (substituted) naphthyl group, or a (substituted) naphtyl-lower group. The compounds of the present invention have inhibitory effects on endopeptidase 24.

Abstract: A compound of the formula ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, phenyl-lower alkyl, lower alkanoyl or benzoyl, and each phenyl in the phenyl-lower alkyl and the benzoyl is unsubstituted or substituted by halogen, lower alkyl or alkoxy; R.sup.2 represents a carboxyl or a carboxyl which is converted into an ester, an amide or a hydroxamic acid; R.sup.3 represent a lower alkyl; R.sup.4 represents a lower alkyl; A.sup.1 represents a lower alkylene which is unsubstituted or substituted by a phenyl and the phenyl is unsubstituted or substituted by halogen, lower alkyl or a lower alkoxy; A.sup.2 represents a lower alkylene; A.sup.3 represents a lower alkylene; and Z represents a sulfur or an oxygen. The compounds have inhibitory effects on LTA.sub.4 hydrolase and are useful for treating rheumatic diseases, psoriasis, inflammatory intestinal diseases, gout and cystic fibrosis.

Abstract: This invention relates to novel compounds of the formula ?I!, ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents a lower alkoxy group; A and B are the same or different and each represents a lower alkylene group.The compounds of this invention have affinities for sigma receptors and are useful for therapeutic agents for cerebral neural function disorders such as dementia, depression, schizophrenia and anxiety neurosis, diseases accompanying abnormal immune response and cryptorrhea, digestive ulcer, etc.

Abstract: This invention relates to novel aqueous ophthalmic compositions containing vitamin E or ester thereof as an active ingredient, sorbic acid or salts thereof as a preservative, and surfactant. The composition of this invention is useful for treatment of various eye diseases, especially for cataract.

Abstract: This invention relates to the compounds of the formula [I] which are useful for the treatment of cataracts, and the synthetic intermediates of the formula [II], ##STR1## wherein R.sup.1 is hydroxy which can be protected by a hydroxy protective group;R.sup.2 is lower alkyl;R.sup.3 is hydrogen, lower alkyl, hydroxy, which can be protected by a hydroxy protective group, or lower alkoxy, and the said lower alkyl can be substituted by hydroxy, which can be protected by a hydroxy protective group, amino or lower alkylamino;R.sup.4 is carboxy which can be converted into ester or amide; tetrazolyl; phosphono which can be converted into ester or amide; or sulfonyl which can be converted into ester or amide;R.sup.5 is cyano or lower alkoxy;A is alkylene;B is C.dbd.O, C.dbd.S or CH.sub.2, andis single bond or double bond.

Abstract: This invention relates to the compounds of the formula [I] which are useful for the treatment of cataracts, and the synthetic intermediates of the formula [II], ##STR1## wherein R.sup.1 is hydroxy which can be protected by a protective group;R.sup.2 is lower alkyl;R.sup.3 is hydrogen, lower alkyl, hydroxy, which can be protected by a protective group, or lower alkoxy, and the said lower alkyl can be substituted by hydroxy, which can be protected by a protective group, amino or lower alkylamino;R.sup.4 is tetrazolyl, phosphonol or lower alkyl ester thereof, or sulfonyl or lower alkyl ester thereof, andA is alkylene.

Abstract: A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.